Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues

References

• PapakostasGIFavaMDoes the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDDEur Neuropsychopharmacol2009191344018823760
   PubMed Web of Science ®Google Scholar
• SheltonRCTreatment options for refractory depressionJ Clin Psychiatry199960Suppl 4576110086483
   PubMed Web of Science ®Google Scholar
• PetersenTPapakostasGIPosternakMAEmpirical testing of two models for staging antidepressant treatment resistanceJ Clin Psychopharmacol2005825433634116012276
   PubMed Web of Science ®Google Scholar
• MachadoMIskedjianMRuizIEinarsonTRRemission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trialsCurr Med Res Opin20062291825183716968586
   PubMed Web of Science ®Google Scholar
• MollerHJOutcomes in major depressive disorder: the evolving concept of remission and its implications for treatmentWorld J Biol Psychiatry20089210211418428079
   PubMed Web of Science ®Google Scholar
• TrivediMHRushAJWisniewskiSREvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry20061631284016390886
   PubMed Web of Science ®Google Scholar
• RushAJTrivediMHWisniewskiSRAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportAm J Psychiatry2006163111905191717074942
   PubMed Web of Science ®Google Scholar
• GredenJFThe burden of disease for treatment-resistant depressionJ Clin Psychiatry200162Suppl 16263111480881
   PubMedGoogle Scholar
• KellerMBBolandRJImplications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depressionBiol Psychiatry19984453483609755357
   PubMed Web of Science ®Google Scholar
• ThaseMEFriedmanESBiggsMMCognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D reportAm J Psychiatry2007164573975217475733
   PubMed Web of Science ®Google Scholar
• ThaseMERushAJWhen at first you don’t succeed: sequential strategies for antidepressant nonrespondersJ Clin Psychiatry199758Suppl 1323299402916
   PubMed Web of Science ®Google Scholar
• TrivediMHFavaMWisniewskiSRMedication augmentation after the failure of SSRIs for depressionN Engl J Med2006354121243125216554526
   PubMed Web of Science ®Google Scholar
• SheltonRCPapakostasGIAugmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorderActa Psychiatr Scand2008117425325918190674
   PubMed Web of Science ®Google Scholar
• PapakostasGISheltonRCSmithJFavaMAugmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysisJ Clin Psychiatry200768682683117592905
   PubMed Web of Science ®Google Scholar
• TyrkaARPriceLHMelloMFMelloAFCarpenterLLPsychotic major depression: a benefit-risk assessment of treatment optionsDrug Saf200629649150816752932
   PubMed Web of Science ®Google Scholar
• NelsonJCPikalovABermanRMAugmentation treatment in major depressive disorder: focus on aripiprazoleNeuropsychiatr Dis Treat20084593794819183784
   PubMedGoogle Scholar
• DeeksEDKeatingGMOlanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depressionDrugs20086881115113718484802
   PubMed Web of Science ®Google Scholar
• JansLARiedelWJMarkusCRBloklandASerotonergic vulnerability and depression: assumptions, experimental evidence and implicationsMol Psychiatry200712652254317160067
   PubMed Web of Science ®Google Scholar
• SchidkrautJJThe catecholamine hypothesis of affective disorders: a review of supporting evidenceAm J Psychiatry19651225095225319766
   PubMed Web of Science ®Google Scholar
• ElhwuegiASCentral monoamines and their role in major depressionProg Neuropsychopharmacol Biol Psychiatry200428343545115093950
   PubMed Web of Science ®Google Scholar
• RichelsonEInteractions of antidepressants with neurotransmitter transporters and receptors and their clinical relevanceJ Clin Psychiatry200364Suppl 1351214552650
   PubMed Web of Science ®Google Scholar
• LiottiMMaybergHSMcGinnisSBrannanSLJerabekPUnmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depressionAm J Psychiatry2002159111830184012411216
   PubMed Web of Science ®Google Scholar
• MaybergHSLiottiMBrannanSKReciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadnessAm J Psychiatry1999156567568210327898
   PubMed Web of Science ®Google Scholar
• DrevetsWCBogersWRaichleMEFunctional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolismEur Neuropsychopharmacol20021265274412468016
   PubMed Web of Science ®Google Scholar
• MarekGDumanRSKaplanGBHammerRPNeural circuitry and signaling in depressionBrain Circuitry and Signaling in PsychiatryWashington, DCAmerican Psychiatric Publishing, Inc2002153178
   Google Scholar
• WalshNDWilliamsSCBrammerMJA longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapyBiol Psychiatry20071;62111236124317601497
   PubMed Web of Science ®Google Scholar
• IshizakiJYamamotoHTakahashiTTakedaMYanoMMimuraMChanges in regional cerebral blood flow following antidepressant treatment in late-life depressionInt J Geriatr Psychiatry200823880581118214999
   PubMed Web of Science ®Google Scholar
• VlassenkoAShelineYIFischerKMintunMACerebral perfusion response to successful treatment of depression with different serotoninergic agentsJ Neuropsychiatry Clin Neurosci200416336036315377745
   PubMed Web of Science ®Google Scholar
• DaviesJLloydKRJonesIKBarnesAPilowskyLSChanges in regional cerebral blood flow with venlafaxine in the treatment of major depressionAm J Psychiatry2003160237437612562589
   PubMed Web of Science ®Google Scholar
• TatsumiMGroshanKBlakelyRDRichelsonEPharmacological profile of antidepressants and related compounds at human monoamine transportersEur J Pharmacol19973402–32492589537821
   PubMed Web of Science ®Google Scholar
• CusackBNelsonARichelsonEBinding of antidepressants to human brain receptors: focus on newer generation compoundsPsychopharmacology (Berl)199411445595657855217
   PubMed Web of Science ®Google Scholar
• RosenbaumJFTollefsonGDSchatzbertAFNemeroffCBFluoxetineTextbook of PsychopharmacologyThird Edition edArlington, VAAmerican Psychiatric Publishing, Inc2004231246
   Google Scholar
• SzaboSTdeMCBlierPModulation of noradrenergic neuronal firing by selective serotonin reuptake blockersBr J Pharmacol1999126356857110188964
   PubMed Web of Science ®Google Scholar
• SoderoAPValdomeroACuadraGRRamirezOAOrsingherOALocus coeruleus activity in perinatally protein-deprived rats: effects of fluoxetine administrationEur J Pharmacol20045031–3354215496293
   PubMed Web of Science ®Google Scholar
• WestCHRitchieJCBoss-WilliamsKAWeissJMAntidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neuronsInt J Neuropsychopharmacol200912562764118950545
   PubMed Web of Science ®Google Scholar
• SzaboSTBlierPFunctional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neuronsBrain Res2001922192011730697
   PubMed Web of Science ®Google Scholar
• PriscoSEspositoEDifferential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental areaBr J Pharmacol19951162192319318528581
   PubMed Web of Science ®Google Scholar
• DiMascioMDiGiovanniGDiMatteoVPriscoSEspositoESelective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental areaBrain Res Bull19984665475549744293
   PubMed Web of Science ®Google Scholar
• DiGiovanniGDeDeurwaerderePDiMascioMDiMatteoVEspositoESpampinatoUSelective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis studyNeuroscience199991258759710366016
   PubMed Web of Science ®Google Scholar
• DiMatteoVDiGiovanniGDiMascioMEspositoESB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic systemNeuropharmacology19993881195120510462132
   PubMed Web of Science ®Google Scholar
• DiMatteoVDiGiovanniGDiMascioMEspositoESelective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbensNeuropharmacology19983722652729680252
   PubMed Web of Science ®Google Scholar
• BlierPSzaboSTPotential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxietyJ Clin Psychiatry200566Suppl 8304016336034
   PubMed Web of Science ®Google Scholar
• SeagerMAHuffKDBarthVNPhebusLARasmussenKFluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activityBiol Psychiatry200455111103110915158430
   PubMed Web of Science ®Google Scholar
• GobertARivetJMLejeuneFSerotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the ratSynapse200036320522110819900
   PubMed Web of Science ®Google Scholar
• IchikawaJIshiiHBonaccorsoSFowlerWLO’LaughlinIAMeltzerHY5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine releaseJ Neurochem20017651521153111238736
   PubMed Web of Science ®Google Scholar
• LiegeoisJFIchikawaJMeltzerHY5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent mannerBrain Res2002947215716512176156
   PubMed Web of Science ®Google Scholar
• IchikawaJMeltzerHYR(+)-8-OH-DPAT, a serotonin (1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatumJ Pharmacol Exp Ther199929131227123210565846
   PubMed Web of Science ®Google Scholar
• JentschJDRothRHTaylorJRRole for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug actionProg Brain Res200012643345311105661
   PubMed Web of Science ®Google Scholar
• WeisstaubNVZhouMLiraACortical 5-HT2A receptor signaling modulates anxiety-like behaviors in miceScience2006313578653654016873667
   PubMed Web of Science ®Google Scholar
• FeigerADHeiserJFShrivastavaRKGepirone extended-release: new evidence for efficacy in the treatment of major depressive disorderJ Clin Psychiatry200364324324912716264
   PubMed Web of Science ®Google Scholar
• McGrathPJStewartJWQuitkinFMGepirone treatment of atypical depression: preliminary evidence of serotonergic involvementJ Clin Psychopharmacol19941453473527806692
   PubMed Web of Science ®Google Scholar
• BardeYANeurotrophins: a family of proteins supporting the survival of neuronsProg Clin Biol Res199439045567724649
   PubMedGoogle Scholar
• MartinowichKManjiHLuBNew insights into BDNF function in depression and anxietyNat Neurosci20071091089109317726474
   PubMed Web of Science ®Google Scholar
• DumanRSMonteggiaLMA neurotrophic model for stress-related mood disordersBiol Psychiatry200659121116112716631126
   PubMed Web of Science ®Google Scholar
• SenSDumanRSanacoraGSerum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implicationsBiol Psychiatry200864652753218571629
   PubMed Web of Science ®Google Scholar
• CastrenEVoikarVRantamakiTRole of neurotrophic factors in depressionCurr Opin Pharmacol200771182117049922
   PubMed Web of Science ®Google Scholar
• LuoCXuHLiXMPost-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapineBrain Res200410251–219420215464760
   PubMed Web of Science ®Google Scholar
• SheltonRCTollefsonGDTohenMA novel augmentation strategy for treating resistant major depressionAm J Psychiatry2001158113113411136647
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• Clinical Global ImpressionsGuyWECDEU Assessment Manual for Psychopharmacology1976Rockville, MDU.S. Department of Health, Education, and Welfare DHEW Publication No. (ADM) 76–338
   Google Scholar
• SheltonRCWilliamsonDJCoryaSAOlanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistanceJ Clin Psychiatry200566101289129716259543
   PubMed Web of Science ®Google Scholar
• CoryaSAWilliamsonDSangerTMBriggsSDCaseMTollefsonGA randomized, double-blind comparison of olanzapine/ fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depressionDepress Anxiety200623636437216710853
   PubMed Web of Science ®Google Scholar
• ThaseMECoryaSAOsuntokunOA randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorderJ Clin Psychiatry200768222423617335320
   PubMed Web of Science ®Google Scholar
• HamiltonMGuyWHamiton Anxiety ScaleECDEU Assessment Manual for Psychopharmacology1931981976Rockville, MDU.S. Department of Health, Education, and Welfare
   Google Scholar
• SheehanDVHarnett-SheehanKRajBAThe measurement of disabilityInt Clin Psychopharmacol199611Suppl 389958923116
   PubMed Web of Science ®Google Scholar
• CoryaSAAndersenSWDetkeHCLong-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label studyJ Clin Psychiatry200364111349135614658950
   PubMed Web of Science ®Google Scholar
• SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar
• BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
   PubMed Web of Science ®Google Scholar
• GuyWAbnormal Involuntary Movement Scale (AIMS)ECDEU Assessment Manual for Psychopharmacology5345371976Rockville, MDNational Institute for Mental Health
   Google Scholar
• BermanRMMarcusRNSwaninkRThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768684385317592907
   PubMed Web of Science ®Google Scholar
• MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200828215616518344725
   PubMed Web of Science ®Google Scholar
• ThaseMEQuetiapine monotherapy for bipolar depressionNeuropsychiatr Dis Treat200841112118728771
   PubMedGoogle Scholar
• DalyEJTrivediMHA review of quetiapine in combination with antidepressant therapy in patients with depressionNeuropsychiatr Dis Treat20073685586719300621
   PubMedGoogle Scholar
• DoddSBerkMOlanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utilityExpert Rev Neurother2008891299130618759541
   PubMedGoogle Scholar
• TrivediMHThaseMEOsuntokunOAn integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depressionJ Clin Psychiatry200970338739619284928
   PubMed Web of Science ®Google Scholar
• TohenMVietaECalabreseJEfficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depressionArch Gen Psychiatry200360111079108814609883
   PubMed Web of Science ®Google Scholar
• BrownEBMcElroySLKeckPEJrA 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depressionJ Clin Psychiatry20066771025103316889444
   PubMed Web of Science ®Google Scholar
• BrownEDunnerDLMcElroySLOlanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar I depressionInt J Neuropsychopharmacol20081211110 [Epub ahead of print]
   Web of Science ®Google Scholar
• AmsterdamJDShultsJComparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression – lack of manic inductionJ Affect Disord200587112113015923042
   PubMed Web of Science ®Google Scholar
• TakahashiHKamataMYoshidaKHiguchiHIshigookaJAugmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case seriesHum Psychopharmacol200823321722018172909
   PubMed Web of Science ®Google Scholar
• RasmussenKCreating more effective antidepressants: clues from the clinicDrug Discov Today20061113–1462363116793531
   PubMed Web of Science ®Google Scholar
• AllisonDBMentoreJLHeoMAntipsychotic-induced weight gain: a comprehensive research synthesisAm J Psychiatry1999156111686169610553730
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of ObesityConsensus development conference on antipsychotic drugs and obesity and diabetesDiabetes Care20042759660114747245
   PubMed Web of Science ®Google Scholar
• NewcomerJWSecond-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature reviewCNS Drugs200519Suppl 119315998156
   PubMed Web of Science ®Google Scholar
• IosifescuDVTreating depression in the medically illPsychiatr Clin North Am2007301779017362805
   PubMed Web of Science ®Google Scholar
• LettHSBlumenthalJABabyakMADepression as a risk factor for coronary artery disease: evidence, mechanisms, and treatmentPsychosom Med200466330531515184688
   PubMed Web of Science ®Google Scholar
• DavidsonKWKupferDJBiggerJTAssessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group ReportPsychosom Med200668564565017012516
   PubMed Web of Science ®Google Scholar
• Frasure-SmithNLesperanceFDepression--a cardiac risk factor in search of a treatmentJAMA2003289233171317312813125
   PubMed Web of Science ®Google Scholar
• HennekensCHPrevention of premature mortality among patients with schizophrenia: the need for primary prevention efforts in cardiovascular diseaseCNS Spectr2008136 Suppl 1091018567981
   PubMed Web of Science ®Google Scholar
• Roshanaei-MoghaddamBKatonWPremature mortality from general medical illnesses among persons with bipolar disorder: a reviewPsychiatr Serv200960214715619176408
   PubMed Web of Science ®Google Scholar
• BerlimMTTureckiGWhat is the meaning of treatment resistant/ refractory major depression (TRD)? A systematic review of current randomized trialsEur Neuropsychopharmacol2007171169670717521891
   PubMed Web of Science ®Google Scholar
• KellerMBIssues in treatment-resistant depressionJ Clin Psychiatry200566Suppl 851216336031
   PubMed Web of Science ®Google Scholar
• RushAJThaseMEDubeSResearch issues in the study of difficult-to-treat depressionBiol Psychiatry200353874375312706958
   PubMed Web of Science ®Google Scholar
• SackeimHAThe definition and meaning of treatment-resistant depressionJ Clin Psychiatry200162Suppl 16101711480879
   PubMedGoogle Scholar
• TrivediMHMorrisDWGrannemannBDMahadiSSymptom clusters as predictors of late response to antidepressant treatmentJ Clin Psychiatry20056681064107016086624
   PubMed Web of Science ®Google Scholar